Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS.

NCT05192200 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05192200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05192200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS.
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2021
Completion date
November 20, 2023
Enrollment
24 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis